In summary, by informing the prevalence of KRAS and EGFR alterations, the associated genomic co-alterations, and patterns of immunotherapy-associated biomarkers among different ancestry groups, our findings offer the potential to help formulate new therapeutic hypotheses, propel evaluation of new therapeutic strategies, and influence public health policies that may aid alleviation of cancer disparities. This evidence concerns the gene KRAS and cancer.